Watch KROS. Know when insiders buy.
One email the day a filing lands. Free.
Work order
30
FLAG · insiders 45, shorts 14
Insiders, 90 days
−$101K
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $224.4MP/E —DIV YIELD —FCF YIELD -21.60%REV TTM $14.5M −93.7%NET INCOME −$83.2M −543.0%NET CASH —52W 9.91 – 21.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$30.9M | −$28.7M | — | -1.45 | −$20.4M | $155K | −$20.6M | Aug 3 |
| Q1 2026 · Mar 31 | $32K | −100.0% | — | −$25.9M | −$23.7M | −116.0% | -1.21 | −$3.5M | $73K | −$3.6M | Aug 3 |
| Q4 2025 · Dec 31derived | $380K | — | — | −$29.3M | −$23.5M | — | -0.38 | −$27.3M | $134K | −$27.4M | Mar 4 |
| Q3 2025 · Sep 30 | $14.1M | — | — | −$15.4M | −$7.3M | — | -0.18 | $3.2M | $132K | $3.1M | Nov 5 |
| Q2 2025 · Jun 30 | $18.2M | — | — | −$39.8M | −$30.7M | — | -0.76 | −$29.6M | $720K | −$30.3M | Aug 3 |
| Q1 2025 · Mar 31 | $211.2M | — | — | $152M | $148.5M | — | 3.62 | $161.2M | $565K | $160.6M | Aug 3 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$53.3M | −$46M | — | -1.12 | −$46M | $289K | −$46.3M | Mar 4 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$58.7M | −$53M | — | -1.41 | −$30.5M | $386K | −$30.9M | Nov 5 |
| Q2 2024 · Jun 30 | $0 | — | — | −$50.4M | −$45.3M | — | -1.25 | −$39.8M | $310K | −$40.1M | Nov 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$48.5M | −$43.1M | — | -1.21 | −$44.6M | $946K | −$45.5M | Nov 5 |
| Q4 2023 · Dec 31derived | $143K | — | — | −$46.5M | −$40.2M | — | -1.34 | −$25.5M | $541K | −$26M | Feb 26 |
| Q3 2023 · Sep 30 | $8K | — | — | −$43.3M | −$39.4M | — | -1.33 | −$34M | $550K | −$34.5M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $243.9M | — | $67.6M | $87M | 35.7% | 2.30 | $107.5M | $1.6M | $106M | $375M | — |
| FY2024 · to Dec 31 | $0 | — | −$210.8M | −$187.4M | — | -5.00 | −$160.9M | $1.9M | −$162.8M | $0 | — |
| FY2023 · to Dec 31 | $151K | — | −$169.9M | −$153M | -101319.2% | -5.20 | −$124.5M | $2.5M | −$127M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$114.8M | −$104.7M | — | -4.15 | −$70.1M | $1.2M | −$71.3M | — | — |
| FY2021 · to Dec 31 | $20.1M | — | −$56.4M | −$58.7M | -292.3% | -2.52 | −$62.1M | $1M | −$63.2M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$46.7M | −$45.4M | — | -2.93 | −$36.9M | $294K | −$37.2M | — | — |
Every number comes from Keros Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.